
Theolytics
Developer of a best-in-class oncolytic immunotherapy platform designed to deliver targeted and effective treatments for patients with difficult-to-treat cancers. The company offers a proprietary adeno...
Valuation
$71M
Latest known
Share Price
N/A
Total Raised
$84.6M
Last Round
N/A